#TNBC

A groundbreaking advancement in cancer prevention has emerged through the development of a vaccine aimed at halting triple-negative breast cancer (TNBC) before it even begins. This promising development deepens our understanding of how proactive immunological defenses can target aggressive forms of cancer. TNBC is notably difficult to treat, and this new vaccine—resulting from a collaboration between Anixa Biosciences and the Cleveland Clinic—marks a significant step forward in preventing this challenging condition.